Biosign Corporate Update
TORONTO, March 1, 2013 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) ("Biosign" or the "Company") today annonced the following:
Restatement of the Engagement of Mr. Peter Hamilton: With respect to the previously announced appointment of Mr. Peter Hamilton to the position of Executive Vice President of Business Development of the Company on December 21, 2012, due to a revision in the Company's restructuring plan, Mr. Hamilton's relationship with the Company has been changed. Rosseau Consulting Inc., of which Mr. Hamilton is an employee, has been retained as a consultant to provide business development services to the Company. As part of such services, Mr. Hamilton will assist in the provision of such services with the title of Business Development Consultant. As a result, Mr. Hamilton is not an executive or employee of the Company and his relationship to Biosign is that of an independent consultant.
Resignation of Director: Biosign announces the resignation of director Mr. Zoheb Rizvi, effective immediately. Mr. Rizvi is the General Manager of Markham, Ontario based Prospec Specialties Inc., and is leaving the board to devote his time to growing that company. The Board and management wish to sincerely thank Mr. Rizvi for his service as a director, and wish him great success in all his future endeavours. Biosign has begun a selection process to replace Mr. Rizvi on the board. With this resignation, the Board now consists of independent directors Senator Alfonse D'Amato and Mr. Jason Meretsky, Chairman John Rizvi, and Biosign CEO Robert Kaul.
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides automated, computer enabled health information products. Key applications include the noninvasive monitoring of vital signs including blood pressure, pulse rate and breathing rate, enhanced with web services. The Company's Pulsewave™ medical device technology powers data collection for clinical decision support, self-care, wellness and disease management, while it's Healthanywhere™ software suite offers industry-leading remote patient monitoring solutions. The Company offers a number of cardiovascular screening programs for consumers under its Heart Friendly™ brand, including Heart Friendly™ Dentist. For more information on Biosign, please visit www.biosign.com
This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in, Biosign's filings with Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Biosign Technologies Inc.For further information:
Biosign Contact Information
Chief Executive Officer
Phone: (416) 218-9800 ext. 201